Could a peptide drug slow Alzheimer's? large trial launches
Disease control
Not yet recruiting
This Phase 3 trial tests whether a daily injection of GV1001 can slow cognitive decline in 750 people with moderate-to-severe Alzheimer's. Participants will receive either the drug or a placebo for 24 weeks. Researchers will measure changes in thinking, memory, and daily function…
Phase: PHASE3 • Sponsor: Samsung Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC